Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

What Medarex Has To Offer At $2.4 Billion

Executive Summary

Bristol-Myers Squibb's July 22 offer to buy Medarex for $2.4 billion seems to be a coup for the biotech. While most biotechs are struggling to raise money, Medarex enticed a suitor to pay nearly double its recent stock price
Advertisement

Related Content

20 Drugs That Got Their Start, In Part, With US Public Funding
Bristol’s Next CEO Is Caforio, Tasked With Leading Immuno-Oncology Charge
Deals Of The Week Ponders When $2.1 Billion Is A Steal
Deals Of The Week Untangles The String Of Pearls
Yervoy Survival Data From First-Line Study Sealed The Deal For FDA Approval
Yervoy Survival Data From First-Line Study Sealed The Deal For FDA Approval
Bristol's Immuno-Oncology Leadership Stake Lies In Ipilimumab's Promise
Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String
Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String
Medarex/Bristol Myers Squibbs’ Ipilimumab Shows Off Long-Term Survival Data At ASCO

Topics

Advertisement
UsernamePublicRestriction

Register

PS051341

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel